Reichert, Z. R., Hussain, M. H. A., Lovett, J. L., Kocherginsky, M., Paller, C. J., Agarwal, N., Adra, N., Zhang, J., Picus, J., Szmulewitz, R. Z., Kuzel, T. M., Tagawa, S. T., Bazzi, L. A., Whang, Y. E., Stephenson, R. D., Dreicer, R., Shevrin, D., Rettig, M., Antonarakis, E. S., Morgan, T. M. (2025). Circulating tumor cell expression analysis from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.199